ORAMED PHARMACEUTICALS INC.

Form SC 13G July 13, 2018

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934*

(Amendment No.)*

Oramed Pharmaceuticals Inc

(Name of Issuer)

Common Stock, \$.012 par value

(Title of Class of Securities)

68403P203

(CUSIP Number)

July 13, 2018

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

^{*} The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

$\textbf{CUSIP No. 68403P203} \ \ \text{Page 2 of 7}$

	NAME OF REPORTING PERSONS Altium Capital Management, LP	
1		
	I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) EIN: 82-2066653	
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP	(a) (b)
3	SEC USE ONLY CITIZENSHIP OR PLACE OF	(-)
4	ORGANIZATION	
NUMBER O SHARES	Delaware, United States of America SOLE VOTING 5 0	
BENEFICIA OWNED BY	972,000	
EACH REPORTING	0	
PERSON WITH:	SHARED DISPOSITIVE POWER 8 972,000	
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
10 11	972,000 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9	•
12	5.61%* TYPE OF REPORTING PERSON IA	

*Based upon 17,362,325 shares of common stock outstanding as of July 3, 2018, the trade date.

CUSIP No. 68403P203 Page 3 of 7

NAME OF REPORTING PERSONS

```
Altium Growth Fund, LP
1
          I.R.S. IDENTIFICATION NO. OF
          ABOVE PERSONS
          (ENTITIES ONLY) EIN: 82-2105101
          CHECK THE APPROPRIATE BOX IF \,^{(a)}
2
          A MEMBER OF A GROUP
                                         (b)
          SEC USE ONLY
3
          CITIZENSHIP OR PLACE OF
          ORGANIZATION
4
          Delaware, United States of America
              SOLE VOTING
NUMBER OF
SHARES
              0
BENEFICIALLY 6
              SHARED VOTING POWER
OWNED BY
              972,000
              SOLE DISPOSITIVE POWER
EACH
             7
REPORTING
              0
              SHARED DISPOSITIVE POWER
PERSON
             8
WITH:
              972,000
          AGGREGATE AMOUNT
          BENEFICIALLY OWNED BY EACH
          REPORTING PERSON
9
          972,000
          CHECK BOX IF THE AGGREGATE
10
          AMOUNT IN ROW 9 EXCLUDES
          CERTAIN SHARES
          PERCENT OF CLASS REPRESENTED
          BY AMOUNT IN ROW 9
11
          5.61%*
          TYPE OF REPORTING PERSON
12
          PN
```

^{*}Based upon 17,362,325 shares of common stock outstanding as of July 3, 2018, the trade date.

$\textbf{CUSIP No. 68403P203} \ \ \text{Page 4 of 7}$

	NAME OF REPORTING PERSONS	
	Altium Capital Growth GP, LLC	
1		
	I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) EIN: 82-2086430	
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (b)	
3	SEC USE ONLY CITIZENSHIP OR PLACE OF	,
4	ORGANIZATION	
NUMBER O SHARES	Delaware, United States of America SOLE VOTING 5 0	
BENEFICIA OWNED BY	6	
EACH REPORTING	7	
PERSON WITH:	SHARED DISPOSITIVE POWER 8 972,000	
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
10	972,000 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9	
11	5.61%*	
12	TYPE OF REPORTING PERSON PN	

*Based upon 17,362,325 shares of common stock outstanding as of July 3, 2018, the trade date.

CUSIP No. 68403P203 Page 5 of 7

Name

of Oramed Pharmaceuticals, Inc (the "Issuer") Item 1(a).

Issuer:

Address

of

Issuer's Pil42 W. 57th Street, 11th Floor, Principal

Item 1(b). New York, NY 10019 Executive

Offices:

Item 2(a). Name of Person Filing:

This statement is jointly filed by and on behalf of each of Altium Growth Fund, LP, Altium Capital Management, LLC, and Altium Growth GP, LLC. Altium Growth Fund, LP is the record and direct beneficial owner of the securities covered by this statement. Altium Capital Management, LP is the investment adviser of, and may be deemed to beneficially own securities, owned by, Altium Growth Fund, LP. Altium Growth GP, LLC is the general partner of, and may be deemed to beneficially own securities owned by, Altium Growth Fund, LP.

Each reporting person declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, the beneficial owner of any securities covered by this statement.

Each of the reporting persons may be deemed to be a member of a group with respect to the Issuer or securities of the Issuer for the purposes of Section 13(d) or 13(g) of the Act. Each of the reporting persons declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, (i) acting (or has agreed or is agreeing to act together with any other person) as a partnership, limited partnership, syndicate, or other group for the purpose of acquiring, holding, or disposing of securities of the Issuer or otherwise with respect to the Issuer or any securities of the Issuer or (ii) a member of any group with respect to the Issuer or any securities of the Issuer.

Address of Principal Business Office or, if None, Residence:

Item 2(b). The address of the principal business office of each of the reporting persons is 551 Fifth Ave, FL 19 New York, NY 10176

Item 2(c). Citizenship:

See Item 4 on the cover page(s) hereto.

Item 2(d). Title of Class of Securities:

Common Stock

Item 2(e). CUSIP Number: <u>68403P203</u>

If This Statement is Filed Pursuant to Item 3. §§240.13d-1(b), or 240.13d-2(b) or (c), Check Whether the Person Filing is a:

- (a) Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
- (b) Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
- (c) Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).

Investment company registered under (d) Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

(e) An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

CUSIP No. 68403P203 Page 6 of 7

- (f) An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
- (g) A parent holding company or control person in accordance with §240.13d-1(b)(ii)(G);
- (h) A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i) A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);
- (j) Group, in accordance with $\S240.13d-1(b)(1)(ii)(J)$.

Item 4 Ownership.

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

- (a) Amount beneficially owned: See Item 9 on the cover page(s) hereto.
- (b) Percent of class: See Item 11 on the cover page(s) hereto.
- (c) Number of shares as to which such person has:
 - (i) Sole power to vote or to direct the vote: See Item 5 on the cover page(s) hereto.
 - (ii) Shared power to vote or to direct the vote: See Item 6 on the cover page(s) hereto.
 - (iii) Sole power to dispose or to direct the disposition of: See Item 7 on the cover page(s) hereto.
 - (iv) Shared power to dispose or to direct the disposition of: See Item 8 on the cover page(s) hereto.

CUSIP No. 68403P203 Page 7 of 7

Item

5.

Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following

Item

6.

Ownership of More than Five Percent on Behalf of Another Person.

Not applicable

Item Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by 7.

the Parent Holding Company or Control Person.

Not applicable

Item

Identification and Classification of Members of the Group. 8.

Not applicable

Item

Notice of Dissolution of Group. 9.

Not applicable

Item

Certification. 10.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: July 12, 2018

Altium Capital Management, LP

/s/ Jacob Gottlieb By: Jacob Gottlieb Name:

Title: **CEO**

Altium Growth Fund, LP

Altium Growth GP, LLC By:

General Partner Its:

Signature:/s/ Jacob Gottlieb Name: Jacob Gottlieb

Title: CEO

Altium Growth GP, LLC

By: /s/ Jacob Gottlieb Name: Jacob Gottlieb

Title: CEO